Wegovy & Mounjaro: UK Issues Pancreatitis & Death Warning

UK Health Agency Warns of Pancreatitis Risk Linked to Obesity and Diabetes Drugs

A growing number of reports have linked popular weight loss and diabetes medications, including Mounjaro and Wegovy, to severe inflammation of the pancreas, prompting a renewed warning from UK health officials. The alert, issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday, underscores the importance of patient awareness and physician vigilance regarding potential adverse effects associated with these increasingly prescribed drugs.

The MHRA’s guidance applies to medications that mimic the action of GLP-1, such as Wegovy, and those that mimic GIP, like Mounjaro. Similar safety alerts have already been issued in the United States, signaling a broader concern regarding these classes of drugs.

Did you know? – GLP-1 and GIP are incretin hormones that help regulate blood sugar levels. These medications amplify those effects, leading to weight loss and improved diabetes control, but also potential side effects.

Serious Cases, Though Rare, demand Attention

While severe cases of pancreatitis are uncommon, the MHRA emphasized that reported episodes have been particularly severe. The agency received nearly 1,300 reports of the condition associated with these medications between 2007 and October 2025,including 19 deaths and 24 cases of necrotizing pancreatitis,a life-threatening condition where pancreatic tissue dies. Approximately 25 million packs of these medications have been dispensed across the United Kingdom in the last five years.

“Doctors and patients should be aware that some episodes were particularly severe,” a senior official stated,reinforcing the need for careful monitoring.

Pharmaceutical Companies Respond

Both Novo Nordisk, the manufacturer of Wegovy, and Eli Lilly, the maker of Mounjaro, have responded to the concerns. novo Nordisk affirmed that patients should only utilize these medications under the direct supervision of a healthcare professional, who can provide extensive guidance on potential side effects.According to a company release, the benefit-risk profile of GLP-1-based medicines remains positive.

Eli Lilly indicated that inflammation of the pancreas may affect up to 1 in 100 people taking Mounjaro and recommended that individuals with a prior history of pancreatitis consult thier physicians before starting the medication. The company also stated it takes all reports regarding patient safety seriously and is committed to working with healthcare providers to ensure thay have access to the latest safety details.

Pro tip – If you are taking Wegovy or Mounjaro, discuss any new or worsening abdominal pain with your doctor promptly. Don’t delay seeking medical attention.

Recognizing the Symptoms and Addressing Potential Gaps in Care

The MHRA advises individuals using obesity medications to seek immediate medical attention if they experience severe and persistent abdominal pain that radiates to the back, potentially accompanied by nausea and vomiting.

A critical concern raised by the agency is the potential for underreporting. Doctors are now being urged to specifically inquire about the use of these medications in patients presenting with relevant symptoms, recognizing that privately purchased prescriptions may not be reflected in records maintained by the British National Health Service (NHS).

This latest advancement highlights the ongoing need for rigorous monitoring and clear communication regarding the safety of these powerful medications as their use continues to expand globally.

Reader question – Have you or someone you know experienced side effects while taking Wegovy or Mounjaro? Share your thoughts on the importance of reporting adverse drug reactions.